N@N

ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 25, 2011

_{//health-fitness.news-articles.net/content/2011/ .. tment-community-meeting-on-february-25-2011.html}
^{Published in Health and Fitness on Tuesday, February 1st 2011 at 12:06 GMT by Market Wire}  

WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc. ] (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, invites investors, journalists and the general public to listen to a live webcast of the Companya™s investment community meeting on February 25, 2011. The webcast will begin at 8:30 a.m. ET and may be accessed through the Investor Information section of the Companya™s website, [ www.immunogen.com ]. The meeting is expected to last approximately three hours, including a short break. An archive of the webcast will be available on the Companya™s website through March 11, 2011.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGena™s collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at [ www.immunogen.com ].